Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997835 | 0.95 | TP53 (0.49) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT | |
| SCHEMBL999215 | 0.94 | MAPT (0.52) | TP53MAPTKMT2AMEN1POLB | |
| SCHEMBL998932 | 0.83 | TP53 (0.43) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT | |
| SCHEMBL998642 | 0.82 | SIRT1 (0.56) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT | |
| SCHEMBL998058 | 0.78 | TP53 (0.54) | TP53MAPT | |
| SCHEMBL997876 | 0.78 | TP53 (0.46) | TP53SMN1; SMN2MAPKAPK2MAPTMAPKAPK5 | |
| SCHEMBL998493 | 0.77 | MAPT (0.73) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT | |
| SCHEMBL998246 | 0.76 | MAPKAPK2 (0.59) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT | |
| SCHEMBL998530 | 0.74 | MAPT (0.61) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT | |
| SCHEMBL6004236 | 0.73 | MAPT (0.60) | SIRT1TP53SMN1; SMN2MAPKAPK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | SIRT1 241/4885TP53 945/4885SMN1; SMN2 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.